S&P 500   2,986.20 (-0.39%)
DOW   26,770.20 (-0.95%)
QQQ   191.69 (-0.96%)
AAPL   236.41 (+0.48%)
FB   185.85 (-2.38%)
MSFT   137.41 (-1.63%)
GOOGL   1,244.41 (-0.67%)
AMZN   1,757.51 (-1.68%)
CGC   20.21 (-2.65%)
NVDA   190.49 (-1.96%)
MU   43.47 (-4.46%)
BABA   169.13 (-4.37%)
GE   8.96 (-0.88%)
TSLA   256.95 (-1.92%)
AMD   30.97 (-0.55%)
T   38.47 (+1.75%)
F   9.29 (+1.98%)
ACB   3.68 (-5.40%)
PRI   123.53 (-0.44%)
NFLX   275.30 (-6.15%)
BAC   30.35 (+0.30%)
GILD   64.91 (-0.49%)
DIS   130.89 (-1.12%)
S&P 500   2,986.20 (-0.39%)
DOW   26,770.20 (-0.95%)
QQQ   191.69 (-0.96%)
AAPL   236.41 (+0.48%)
FB   185.85 (-2.38%)
MSFT   137.41 (-1.63%)
GOOGL   1,244.41 (-0.67%)
AMZN   1,757.51 (-1.68%)
CGC   20.21 (-2.65%)
NVDA   190.49 (-1.96%)
MU   43.47 (-4.46%)
BABA   169.13 (-4.37%)
GE   8.96 (-0.88%)
TSLA   256.95 (-1.92%)
AMD   30.97 (-0.55%)
T   38.47 (+1.75%)
F   9.29 (+1.98%)
ACB   3.68 (-5.40%)
PRI   123.53 (-0.44%)
NFLX   275.30 (-6.15%)
BAC   30.35 (+0.30%)
GILD   64.91 (-0.49%)
DIS   130.89 (-1.12%)
Log in

ProQR Therapeutics News Headlines (NASDAQ:PRQR)

$6.45
-0.34 (-5.01 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
$6.27
Now: $6.45
$6.89
50-Day Range
$5.80
MA: $6.68
$7.56
52-Week Range
$5.49
Now: $6.45
$24.00
Volume253,612 shs
Average Volume207,047 shs
Market Capitalization$250.73 million
P/E RatioN/A
Dividend YieldN/A
Beta0.15

Headlines

ProQR Therapeutics (NASDAQ PRQR) News Headlines

Source:
DateHeadline
ProQR Therapeutics NV (NASDAQ:PRQR) Sees Large Decline in Short InterestProQR Therapeutics NV (NASDAQ:PRQR) Sees Large Decline in Short Interest
www.americanbankingnews.com - October 16 at 6:08 PM
ProQR prices stock offering; shares down 12% after hoursProQR prices stock offering; shares down 12% after hours
seekingalpha.com - October 16 at 12:20 AM
ProQR Prices $50 Million Underwritten Public Offering of Ordinary SharesProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares
finance.yahoo.com - October 16 at 12:20 AM
ProQRs sepofarsen nabs Rare Pediatric Disease status in U.S. for LCA10ProQR's sepofarsen nabs Rare Pediatric Disease status in U.S. for LCA10
seekingalpha.com - October 15 at 7:19 PM
Chardan Capital Reaffirms Buy Rating for ProQR Therapeutics (NASDAQ:PRQR)Chardan Capital Reaffirms Buy Rating for ProQR Therapeutics (NASDAQ:PRQR)
www.americanbankingnews.com - October 11 at 10:02 PM
ProQR Therapeutics (PRQR) Sepofarsen Phase 1/2 Trial Topline Results - SlideshowProQR Therapeutics (PRQR) Sepofarsen Phase 1/2 Trial Topline Results - Slideshow
seekingalpha.com - October 11 at 6:44 PM
Citigroup Increases ProQR Therapeutics (NASDAQ:PRQR) Price Target to $40.00Citigroup Increases ProQR Therapeutics (NASDAQ:PRQR) Price Target to $40.00
www.americanbankingnews.com - October 11 at 2:22 PM
ProQR Therapeutics N.V.: ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 PatientsProQR Therapeutics N.V.: ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients
www.finanznachrichten.de - October 10 at 7:26 AM
ProQRs sepofarsen shows positive action in Phase 1/2 study in LCA10ProQR's sepofarsen shows positive action in Phase 1/2 study in LCA10
seekingalpha.com - October 10 at 7:26 AM
ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 PatientsProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients
finance.yahoo.com - October 10 at 7:26 AM
ProQR Therapeutics NV (NASDAQ:PRQR) Given Average Rating of "Buy" by AnalystsProQR Therapeutics NV (NASDAQ:PRQR) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - October 9 at 1:48 AM
ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAOProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO
finance.yahoo.com - October 7 at 9:04 AM
ProQR Therapeutics Enters Oversold TerritoryProQR Therapeutics Enters Oversold Territory
finance.yahoo.com - October 1 at 4:54 PM
ProQR to Present at Two Investor Conferences in OctoberProQR to Present at Two Investor Conferences in October
finance.yahoo.com - September 30 at 7:44 AM
Cantor Fitzgerald Weighs in on ProQR Therapeutics NVs FY2019 Earnings (NASDAQ:PRQR)Cantor Fitzgerald Weighs in on ProQR Therapeutics NV's FY2019 Earnings (NASDAQ:PRQR)
www.americanbankingnews.com - September 27 at 6:29 AM
Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?
finance.yahoo.com - September 24 at 3:49 PM
ProQR Therapeutics: An In-Depth AssessmentProQR Therapeutics: An In-Depth Assessment
seekingalpha.com - September 17 at 1:13 AM
ProQRs QR-1123 Fast Trackd for vision loss disorder; shares up 2%ProQR's QR-1123 Fast Track'd for vision loss disorder; shares up 2%
seekingalpha.com - September 9 at 2:24 PM
ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis PigmentosaProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
finance.yahoo.com - September 9 at 2:24 PM
Mallinckrodt Enrolls First Patient in Liver Disease StudyMallinckrodt Enrolls First Patient in Liver Disease Study
finance.yahoo.com - August 13 at 6:17 PM
ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP)ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP)
finance.yahoo.com - August 12 at 9:32 AM
ProQR (PRQR) Reports Q2 Loss, Misses Revenue EstimatesProQR (PRQR) Reports Q2 Loss, Misses Revenue Estimates
finance.yahoo.com - August 7 at 5:16 PM
ProQR Announces Financial Results for the Second Quarter of 2019ProQR Announces Financial Results for the Second Quarter of 2019
finance.yahoo.com - August 7 at 10:42 AM
ProQR Therapeutics N.V.: European Medicines Agency Grants PRIME Access to ProQRs Sepofarsen for Lebers Congenital Amaurosis 10ProQR Therapeutics N.V.: European Medicines Agency Grants PRIME Access to ProQR's Sepofarsen for Leber's Congenital Amaurosis 10
www.finanznachrichten.de - July 29 at 11:44 PM
EMA grants PRIME access to ProQr’s sepofarsen for LCA10EMA grants PRIME access to ProQr’s sepofarsen for LCA10
seekingalpha.com - July 29 at 6:44 PM
European Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10European Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10
finance.yahoo.com - July 29 at 8:27 AM
What Did ProQR Therapeutics N.V.s (NASDAQ:PRQR) CEO Take Home Last Year?What Did ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Take Home Last Year?
finance.yahoo.com - July 26 at 6:37 PM
What Did ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Take Home Last Year?What Did ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Take Home Last Year?
finance.yahoo.com - July 26 at 6:37 PM
ProQR up 13% ahead of QR-421a presentationProQR up 13% ahead of QR-421a presentation
seekingalpha.com - July 12 at 5:21 PM
ProQR Announces Presentation on QR-421a Program in Ophthalmology at Usher Syndrome Coalition Conference in JulyProQR Announces Presentation on QR-421a Program in Ophthalmology at Usher Syndrome Coalition Conference in July
finance.yahoo.com - July 2 at 9:47 AM
Here’s What Hedge Funds Think About ProQR Therapeutics NV (PRQR)Here’s What Hedge Funds Think About ProQR Therapeutics NV (PRQR)
finance.yahoo.com - June 30 at 9:33 AM
ProQR to Present at the JMP Securities Life Sciences ConferenceProQR to Present at the JMP Securities Life Sciences Conference
finance.yahoo.com - June 3 at 9:41 AM
Did Business Growth Power ProQR Therapeuticss (NASDAQ:PRQR) Share Price Gain of 153%?Did Business Growth Power ProQR Therapeutics's (NASDAQ:PRQR) Share Price Gain of 153%?
finance.yahoo.com - May 27 at 5:32 PM
Did Business Growth Power ProQR Therapeutics's (NASDAQ:PRQR) Share Price Gain of 153%?Did Business Growth Power ProQR Therapeutics's (NASDAQ:PRQR) Share Price Gain of 153%?
finance.yahoo.com - May 27 at 5:32 PM
ProQR Therapeutics: Near-Term Readout On The HorizonProQR Therapeutics: Near-Term Readout On The Horizon
seekingalpha.com - May 23 at 9:43 AM
ProQR to Present at the RBC Capital Markets Healthcare ConferenceProQR to Present at the RBC Capital Markets Healthcare Conference
finance.yahoo.com - May 15 at 9:47 AM
ProQR (PRQR) Reports Q1 Loss, Misses Revenue EstimatesProQR (PRQR) Reports Q1 Loss, Misses Revenue Estimates
finance.yahoo.com - May 8 at 9:44 AM
ProQR to Present at Three Scientific Conferences in AprilProQR to Present at Three Scientific Conferences in April
finance.yahoo.com - May 1 at 6:02 PM
ProQR Announces Annual Meeting of ShareholdersProQR Announces Annual Meeting of Shareholders
www.globenewswire.com - April 18 at 10:16 AM
ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10
finance.yahoo.com - April 15 at 10:44 AM
ProQR to Present at the H.C. Wainwright Global Life Sciences ConferenceProQR to Present at the H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - April 1 at 10:30 AM
ProQR spins out DEB unitProQR spins out DEB unit
seekingalpha.com - March 26 at 6:06 PM
ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research PartnershipProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership
finance.yahoo.com - March 26 at 6:06 PM
ProQR Therapeutics N.V.: ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2ProQR Therapeutics N.V.: ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2
www.finanznachrichten.de - March 11 at 10:42 AM
ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2
finance.yahoo.com - March 11 at 10:42 AM
ProQR Therapeutics: Whats Bigger, Its Pipeline Or Its 2019 Outlook?ProQR Therapeutics: What's Bigger, Its Pipeline Or Its 2019 Outlook?
seekingalpha.com - March 5 at 5:37 PM
ProQR to Present at Cowen Health Care ConferenceProQR to Present at Cowen Health Care Conference
finance.yahoo.com - March 5 at 10:17 AM
Medicines Company (MDCO) Q4 Loss Widens, Inclisiran in Focus - Yahoo FinanceMedicines Company (MDCO) Q4 Loss Widens, Inclisiran in Focus - Yahoo Finance
finance.yahoo.com - March 2 at 9:30 AM
ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial ResultsProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results
finance.yahoo.com - February 27 at 9:56 AM
Form SC 13G ProQR Therapeutics NV Filed by: RTW INVESTMENTS, LP - StreetInsider.comForm SC 13G ProQR Therapeutics NV Filed by: RTW INVESTMENTS, LP - StreetInsider.com
www.streetinsider.com - February 24 at 7:51 PM
This page was last updated on 10/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel